Subtype
Malignant Glioma
CI-CAN-00003164Explore in graph →
589 active trials3 approved drugs67 evidence items
- NCIt
- C4822
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003164Explore in graph →
Clinical trials
2,053 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (325)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03665545 | Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma(IMA950-106) | completed | Phase 1 / Phase 2 | 18 | University Hospital, GenevaOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT02507583 | Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma | completed | Phase 1 | 33 | david andrewsOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT02186509 | Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas | completed | Phase 1 | 17 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT02026271 | A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma | completed | Phase 1 | 40 | Alaunos TherapeuticsINDUSTRY | 1 | Apr 16, 2025 | clinicaltrials |
| NCT02715609 | Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 35 | Washington University School of MedicineOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT02420613 | Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma | completed | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT03893903 | AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma(AMPLIFY-NEOVAC) | completed | Phase 1 | 69 | German Cancer Research CenterOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT03344250 | Phase I EGFR BATs in Newly Diagnosed Glioblastoma | completed | Phase 1 | 16 | University of VirginiaOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT03576612 | GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas(GMCI) | completed | Phase 1 | 41 | Candel Therapeutics, Inc.INDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT02078648 | Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 74 | Stemline Therapeutics, Inc.INDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
| NCT06469138 | A Study to Investigate 14C-bemcentinib in Healthy Male Subjects(8479217) | completed | Phase 1 | 6 | BerGenBio ASAINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT02960230 | H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas | completed | Phase 1 / Phase 2 | 50 | Sabine Mueller, MD, PhDOTHER | 2 | Jan 22, 2025 | clinicaltrials |
| NCT02323880 | Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas | completed | Phase 1 | 59 | Children's Oncology GroupNETWORK | 1 | Jan 14, 2025 | clinicaltrials |
| NCT03914742 | BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations | completed | Phase 1 / Phase 2 | 67 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT04842513 | Multi Peptide Vaccination with XS15 in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed Glioblastoma(GLIO-XS15) | completed | Phase 1 | 15 | University Hospital TuebingenOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT01849146 | Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma | completed | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 1 | Jan 9, 2025 | clinicaltrials |
| NCT01752491 | A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme | completed | Phase 1 | 13 | Joseph J. Cullen, MD, FACSOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT01291420 | Dendritic Cell Vaccination for Patients with Solid Tumors | completed | Phase 1 / Phase 2 | 48 | University Hospital, AntwerpOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT01130077 | A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction with Poly-ICLC in Pediatric Gliomas | completed | Phase 1 | 60 | James FelkerOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT02549833 | Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma | completed | Phase 1 | 28 | Jennie TaylorOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT03232424 | NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma | completed | Phase 1 | 12 | Hackensack Meridian HealthOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT02101905 | Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma | completed | Phase 1 | 29 | National Cancer Institute (NCI)NIH | 1 | Nov 6, 2024 | clinicaltrials |
| NCT01811992 | Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma | completed | Phase 1 | 19 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03234595 | A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma | completed | Phase 1 / Phase 2 | 22 | Everfront Biotech Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03879512 | Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG | completed | Phase 1 / Phase 2 | 24 | Wuerzburg University HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06562621 | Clinical Study on the Safety and Efficacy of Novel Oncolytic Virus in the Treatment of Recurrent Malignant Glioma | completed | Phase 1 / Phase 2 | 38 | Beijing Neurosurgical InstituteOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT04497142 | Effect of Perampanel on Peritumoral Hyperexcitability in HGG | completed | Phase 1 / Phase 2 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT03493932 | Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade | completed | Phase 1 | 21 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 1 | Jul 24, 2024 | clinicaltrials |
| NCT05538572 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | completed | Phase 1 | 22 | Prelude TherapeuticsINDUSTRY | 2 | Jul 1, 2024 | clinicaltrials |
| NCT03434262 | SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors | completed | Phase 1 | 68 | St. Jude Children's Research HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT02654964 | Cancer Stem Cell High-Throughput Drug Screening Study | completed | Phase 1 | 9 | Swedish Medical CenterOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT03043391 | Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children | completed | Phase 1 | 8 | Istari Oncology, Inc.INDUSTRY | 1 | Apr 8, 2024 | clinicaltrials |
| NCT03466450 | Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma(GEINOGLAS) | completed | Phase 1 / Phase 2 | 75 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT02052648 | Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors | completed | Phase 1 / Phase 2 | 160 | NewLink Genetics CorporationINDUSTRY | 1 | Mar 27, 2024 | clinicaltrials |
| NCT02869243 | A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients | completed | Phase 1 | 15 | StemgenINDUSTRY | 3 | Feb 16, 2024 | clinicaltrials |
| NCT01922076 | Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas | completed | Phase 1 | 46 | National Cancer Institute (NCI)NIH | 2 | Jan 31, 2024 | clinicaltrials |
| NCT01811498 | Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM | completed | Phase 1 / Phase 2 | 31 | Northwell HealthOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT02457845 | HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors | completed | Phase 1 | 13 | Gregory K. Friedman, MDOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT04552886 | Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma | completed | Phase 1 | 17 | The Cooper Health SystemOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT04264143 | CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas | completed | Phase 1 | 9 | Luca SzalontayOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT01421524 | Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma | completed | Phase 1 | 271 | CelgeneINDUSTRY | 5 | Dec 12, 2023 | clinicaltrials |
| NCT02315534 | A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma | completed | Phase 1 / Phase 2 | 34 | Sumitomo Pharma America, Inc.INDUSTRY | 2 | Nov 15, 2023 | clinicaltrials |
| NCT02498665 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | completed | Phase 1 | 24 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
| NCT02644460 | Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors(AflacST1501) | completed | Phase 1 | 53 | Emory UniversityOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT02313272 | Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas | completed | Phase 1 | 32 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT02658981 | Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18) | completed | Phase 1 | 63 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT01491893 | PVSRIPO for Recurrent Glioblastoma (GBM)(PVSRIPO) | completed | Phase 1 | 61 | Istari Oncology, Inc.INDUSTRY | 1 | Sep 28, 2023 | clinicaltrials |
| NCT03158389 | NCT Neuro Master Match - N²M² (NOA-20)(N²M²) | completed | Phase 1 / Phase 2 | 228 | University Hospital HeidelbergOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT04119674 | Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 33 | Zhejiang Cancer HospitalOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT02386826 | INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme | completed | Phase 1 | 65 | SCRI Development Innovations, LLCOTHER | 1 | Sep 21, 2023 | clinicaltrials |
Data updated 22 days agoSource updated May 13, 2025source: clinicaltrials